Group 1 - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan [1] - The total amount allocated for the buyback is HKD 2.4726 million [1] - The company plans to repurchase 200,000 shares at a price range of HKD 12.14 to HKD 12.48 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 第 1 頁 共 7 頁 v 1.3.0 FF305 | 於下列日期結束時的結存 (註5及6) 2025年10月23日 | | 870,615,722 | | 22,687,000 | | | 893,302,722 | | --- | --- | --- | --- | --- | --- | --- | --- | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | | | | 購回股份（擬註銷但尚未註銷） | 1). | 250,000 | 0.0327 % | | HKD | 2.25 | | | 變動日期 | 2025年1月8日 | | | | | | | | 購回股份（擬註銷但尚未註銷） | 2). | 156,000 | 0.0204 % | | HKD | 2.39468 | | | 2025年1月10日 | 變動日期 | | | | | | | 呈交日期： 2025年10 ...

Core Viewpoint - On October 22, 35 Hong Kong-listed companies conducted share buybacks, totaling 10.4965 million shares and an amount of 52.7745 million HKD [1][2]. Group 1: Buyback Details - The company with the highest buyback amount on October 22 was AAC Technologies, with a buyback amount of 11.9098 million HKD for 300,000 shares [1][2]. - Linklogis Technology-W followed with a buyback of 2.430 million shares, amounting to 7.4708 million HKD [1][2]. - Mengniu Dairy repurchased 500,000 shares for 7.1714 million HKD [1][2]. Group 2: Year-to-Date Buyback Totals - AAC Technologies has conducted multiple buybacks this year, with a cumulative buyback amount of 858.628 million HKD [2]. - Linklogis Technology-W's total buyback amount for the year reached 225.0668 million HKD [2]. - Mengniu Dairy's year-to-date buyback amount stands at 45.832 million HKD [2]. Group 3: Buyback Volume Rankings - The highest number of shares repurchased on October 22 was by Linklogis Technology-W, with 2.43 million shares [1][2]. - Other notable buybacks in terms of volume included MorningX Technology with 1.064 million shares and China Hengyou Group with 1 million shares [1][2].

Summary of Key Points Core Viewpoint - A total of 30 companies, including major players like 瑞声科技 (AAC Technologies) and 蒙牛乳业 (Mengniu Dairy), conducted share buybacks on October 22, 2025, indicating a trend of companies returning capital to shareholders amidst market conditions. Group 1: Buyback Details - 瑞声科技 (AAC Technologies) had the largest buyback amount, repurchasing 300,000 shares for a total of 11.90 million yuan [1] - 联易融科技-W (Lianyi Technology) repurchased 2.43 million shares, totaling 7.47 million yuan, representing 3.288% of its total share capital [2] - 蒙牛乳业 (Mengniu Dairy) bought back 500,000 shares for 7.17 million yuan, which is 0.517% of its total share capital [2] Group 2: Other Notable Buybacks - 康臣药业 (Kangchen Pharmaceutical) repurchased 283,000 shares for 4.33 million yuan, accounting for 7.969% of its total share capital [2] - 连连数字 (Lianlian Digital) bought back 440,000 shares for 3.54 million yuan, which is 0.138% of its total share capital [2] - 固生堂 (Gushengtang) repurchased 91,300 shares for 2.75 million yuan, representing 2.076% of its total share capital [2] Group 3: Additional Companies Involved - 绿城服务 (Greentown Service) repurchased 216,000 shares for 989,300 yuan, which is 0.007% of its total share capital [2] - 歌礼制药-B (Galactico Pharmaceutical) bought back 100,000 shares for 926,500 yuan, accounting for 0.068% of its total share capital [2] - 医渡科技 (Yidu Technology) repurchased 17,700 shares for 99,800 yuan, representing 0.330% of its total share capital [2]

格隆汇10月22日丨和铂医药-B(02142.HK)公告，10月22日耗资64.7万港元回购5万股。 ...

和铂医药-B(02142)发布公告，于2025年10月22日斥资64.7万港元回购5万股。 ...

智通财经APP讯，和铂医药-B(02142)发布公告，于2025年10月22日斥资64.7万港元回购5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包 ...

Core Insights - The attitude of foreign capital towards Chinese medical assets has dramatically reversed within a year, shifting from a neutral to a positive outlook on the biotechnology sector in China [1][3][7] Group 1: Market Sentiment Shift - Morgan Stanley's report titled "China Biotech: Innovation Dawn" indicates that China's biotechnology sector is now viewed as a critical part of the global new drug supply chain, with projected pharmaceutical revenues reaching $34 billion by 2030 and $220 billion by 2040 [1][3] - The number of foreign institutions conducting research on Chinese biotech companies has surged, with notable firms like State Street Bank and BlackRock showing increased interest [1][2] - The collective buying actions of foreign investors, such as JPMorgan and Citigroup, reflect a significant shift in sentiment towards Chinese innovative drug companies [2][5] Group 2: Investment Dynamics - The efficiency of converting research interest into actual holdings is evident, as seen in the stock price surge of WuXi AppTec, which rose by 6.52% due to increased foreign investment [2] - Major foreign investors have increased their holdings in key Chinese biotech firms, indicating a trend of strategic accumulation among top foreign capital [5][6] - The report highlights that foreign capital is now viewing specific sectors in China as essential assets in the global technology race, with over 90% of U.S. investors expressing plans to increase exposure to Chinese stocks, particularly in biotechnology [6][7] Group 3: Industry Evolution - The narrative surrounding China's pharmaceutical industry has shifted from being cost-driven to innovation-driven, acknowledging the significant advancements in the sector [3][4] - Morgan Stanley and Goldman Sachs both emphasize the growing recognition of China's innovative capabilities in biotechnology, with expectations that several leading biotech firms will reach breakeven by 2025-2026 [4][8] - The report outlines that the Chinese biotech sector is becoming a key player in filling the revenue gaps created by patent expirations in multinational corporations (MNCs), with an estimated $115 billion revenue loss due to patent cliffs by 2035 [8][10] Group 4: Future Projections - By 2040, China's share of FDA-approved drugs is expected to rise from 5% to 35%, with a projected global sales figure exceeding $1.22 trillion even in the most pessimistic scenarios [25][27] - The report anticipates that the collaboration between MNCs and Chinese biotech firms will intensify, driven by the need to address revenue shortfalls from patent expirations [10][14] - The overall improvement in clinical trial data integrity and the increasing number of new molecular entities launched in China are contributing to a more favorable investment landscape [20][22]

Group 1 - Singapore's Government Investment Corporation (GIC) increased its stake in HAPO Pharmaceuticals by acquiring 690,000 shares at an average price of HKD 13.5791 per share, totaling approximately HKD 9.37 million [2] - Following this purchase, GIC's holdings in HAPO Pharmaceuticals rose to 62.975 million shares, increasing its ownership percentage from 6.97% to 7.05% [2] - GIC has made multiple purchases of HAPO Pharmaceuticals this year, including a significant acquisition of 4.0222 million shares for approximately HKD 511 million on August 29, which raised its ownership from 1.62% to 6.37% [2] Group 2 - HAPO Pharmaceuticals has experienced a remarkable revenue increase of 243% over the past year, significantly outpacing the industry growth rate [3] - Despite this substantial revenue growth, HAPO Pharmaceuticals' price-to-earnings ratio remains below the average for the biotechnology industry, indicating considerable future growth potential [3]